Loading
Hepatocellular Carcinoma Treatment and Prognosis / Advances in Oncology and Radiotherapy / Multiple and Secondary Primary Cancers · Journal article
The Lancet Regional Health - Europe · September 1, 2026
A consensus or society position rather than new primary data.
This is a narrative series paper synthesizing epidemiological and etiological trends in European HCC, projecting a >30% increase in cases and deaths by 2050, driven primarily by metabolic dysfunction-associated steatotic liver disease rather than viral hepatitis. The paper frames HCC as largely preventable through modifiable risk factor reduction and offers clinical management and public health policy recommendations.
Journal article. Patients with hepatocellular carcinoma in Europe; focus on those with underlying chronic liver disease.. Europe.
Number of new HCC cases and deaths predicted to increase by over 30% in Europe by 2050 Increase driven largely by metabolic dysfunction-associated steatotic liver disease-related HCC and aging population Over half of all HCC cases predicted to be preventable by targeting modifiable risk factors
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should prioritize prevention and management of metabolic risk factors and viral hepatitis as modifiable drivers of HCC incidence in Europe, and tailor surveillance and treatment strategies across disease stages according to etiological trends. Public health initiatives should target prevention of metabolic dysfunction-associated steatotic liver disease to counteract projected rises in incidence.
A narrative synthesis of epidemiological trends and clinical management implications for HCC in Europe, intended to inform practice and policy rather than report a primary research finding.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should prioritize prevention and management of metabolic risk factors and viral hepatitis as modifiable drivers of HCC incidence in Europe, and tailor surveillance and treatment strategies across disease stages according to etiological trends. Public health initiatives should target prevention of metabolic dysfunction-associated steatotic liver disease to counteract projected rises in incidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Primary liver cancer, of which hepatocellular carcinoma (HCC) represents the vast majority, is on the rise globally. Despite an expected decrease in viral hepatitis-related HCCs, the number of new cases and deaths from liver cancer is predicted to increase by over 30% in 2050 in Europe. This is largely driven by an increase in metabolic dysfunction-associated steatotic liver disease-related HCC and an aging population. Since HCC usually develops in patients with underlying chronic liver disease, over half of all cases appear to be preventable by targeting modifiable risk factors. This series paper summarizes epidemiological and etiological trends of HCC in Europe and their implications for the clinical management of HCC across different disease stages. We discuss public health initiatives and policies to counteract the rising incidence of HCC by focusing on prevention, and highlight additional benefits of etiological treatment for the management and prognosis of patients with HCC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.